Objective: To determine whether healthy males who consumed increased amounts of dietary stearic acid compared with increased dietary palmitic acid through the consumption of commercially available foods, exhibited any changes in plasma lipids, platelet aggregation or platelet activation status.

Design: A randomised cross-over dietary intervention.

Subjects And Interventions: Nine free-living healthy males consumed two experimental diets (stearic acid enriched, diet S, and palmitic acid enriched, diet P) for 3 weeks in a randomised cross-over design separated by a 3 week washout phase. The diets consisted of approximately 30% of energy as fat (30% of which was derived from the treatment diets) providing approximately 13 g/day as stearic acid and 17 g/day as palmitic acid on diet S and approximately 7 g/day as stearic acid and 22 g/day as palmitic acid on diet P. The dietary ratio of stearic to palmitic acids was 0.76 on diet S compared with 0.31 on diet P. Blood samples were collected on days 0 and 21 of each dietary period.

Results: LDL cholesterol levels and platelet aggregation response to the agonist ADP were significantly decreased (P<0.025) in subjects on diet S compared with day 0. Apart from that, there were no significant changes in plasma lipids, platelet aggregation, mean platelet volume and platelet reactivity between diets. There were no significant changes in stearic or palmitic acid levels in plasma phospholipid or triacylglycerol. There was a significant difference in palmitic acid levels in platelet phospholipids between the two diets.

Conclusions: Use of commonly available foods led to a 27% increase in stearic acid (diet S) and a 19% increase in palmitic acid (diet P), on diets S and P respectively, and no significant differences between the two diets in plasma lipoprotein concentrations, platelet aggregation or platelet activation status.

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.ejcn.1601332DOI Listing

Publication Analysis

Top Keywords

stearic acid
16
palmitic acid
16
platelet aggregation
12
stearic palmitic
8
palmitic acids
8
plasma lipids
8
lipids platelet
8
aggregation platelet
8
platelet activation
8
healthy males
8

Similar Publications

An elevated level of saturated fatty acids (SFAs) can cause non-alcoholic fatty liver disease (NAFLD). While n-3 polyunsaturated fatty acids (PUFAs) were shown to improve NAFLD, the effects of n-6 PUFAs in the liver have not been fully elucidated. We examined the association between NAFLD and n-6 PUFAs, particularly dihomo-γ-linolenic acid (DGLA), in patients with type 2 diabetes.

View Article and Find Full Text PDF

Objective: Different aspects of the functions of free fatty acid (FFA) in seminal plasma and their implications on male fertility are known. However, the profile of FFA in seminal plasma in asthenozoospermic patients following antioxidant therapy has not been studied.

Methods: In this case-control study, the total antioxidant capacity (TAC) and FFA profile of the seminal plasma were determined in 80 patients (29 normozoospermic volunteers and 51 asthenozoospermic men) who were treated with antioxidants for three months.

View Article and Find Full Text PDF

Effect of plasma free fatty acids on lung function in male COPD patients.

Sci Rep

January 2025

Department of Internal Medicine, Afzalipour Faculty of Medicine, Afzalipour Hospital Research Center, Kerman University of Medical Sciences, Kerman, Iran.

Inflammation and oxidative stress play a pivotal role in COPD pathogenesis. Free fatty acids (FFA) as signaling molecules through a series of G-proteins coupled receptors, play an important role in regulation of the immune system and oxidative stress. For this reason, we decided to investigate the profile of FFA in the plasma in the COPD patients.

View Article and Find Full Text PDF

Background: Hepatocellular carcinoma (HCC) is a health problem due to multi-drug resistance (MDR). Codelivery of multiple oncotherapy in one cargo as chimeric cancer therapy (CCT) is suggested as a solution for MDR. This study aims to engineer chitosan-coated nanostructure lipid carriers (NLCs) loaded with gefitinib (GF) and simvastatin (SV) as CCT for HCC.

View Article and Find Full Text PDF

The clinical application of curcumin (CUR) is restricted by its low solubility, instability, and poor bioavailability. To overcome these limitations, we developed a novel stearic acid-grafted inulin-based nano-delivery system for CUR encapsulation. The structure of stearoyl inulin (SA-IN) was characterized using Fourier-transform infrared spectroscopy, hydrogen nuclear magnetic resonance, thermogravimetric analysis, and contact angle measurements.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!